Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as ...

Fintel reports that on February 19, 2025, Mizuho upgraded their outlook for Glaukos (NYSE:GKOS) from Neutral to Outperform.

Principal Financial Group Inc. lessened its stake in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 6.9% in the 4th quarter, according to its most recent 13F filing with the Securities and ...

Truist Financial analyst Richard Newitter maintained a Buy rating on Glaukos (GKOS – Research Report) today. The company’s shares closed ...

Needham raised the firm’s price target on Glaukos (GKOS) to $176 from $149 and keeps a Buy rating on the shares after its Q4 results. The ...

Glaukos Corp (GKOS) reports robust sales growth and outlines strategic initiatives for 2025, while navigating currency and ...

Glaukos Corp (NYSE:GKOS) is set to release its Q4 2024 earnings on Feb 20, 2025. The consensus estimate for Q4 2024 revenue ...

The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss of 43 cents per share. The glaucoma treatments developer ...

Glaukos (GKOS) delivered earnings and revenue surprises of 6.98% and 4.71%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Q4 2024 Earnings Conference Call February 20, 2025 4:30 PM ETCompany ParticipantsChris Lewis - Vice President, ...

Rhumbline Advisers lifted its holdings in Glaukos Co. (NYSE:GKOS – Free Report) by 0.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The ...